市場調查報告書
商品編碼
1029311

全球非黑色素瘤皮膚癌市場:行業趨勢、市場份額、規模、增長率、機會和預測(2021-2026)

Non-Melanoma Skin Cancer Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 143 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2015 年至 2020 年,非黑色素瘤皮膚癌治療的全球市場以約 5% 的複合年增長率擴大。非黑色素瘤皮膚癌 (NMSC) 是指皮膚上層惡性細胞過度生長。 NMSCs 包括基底細胞癌、汞細胞癌、鱗狀細胞癌和皮膚 T 細胞淋巴瘤。 NMSC的主要特徵是在皮膚上形成硬塊和鱗狀斑點。治療包括顯微手術、激光治療和冷凍療法等外科手術,以及光動力療法 (PDT)、放射療法和電療法等各種非手術療法,以去除癌細胞。

全球皮膚癌和老年人的增加是推動這一市場增長的重要因素。此外,提高公眾對 NMSC 治療的認識正在推動市場增長。與傳統治療相比,淺表放射治療對患者身體的副作用更少,並且可以在創新的移動設備上進行。這些設備還用於高精度和高靈敏度的皮膚病變的早期診斷。此外,使用電子束的低能量放射治療是一種無痛、無創的治療方法,治療週期短,可以最大限度地減少輻射對周圍健康組織的風險增加。其他因素包括個人健康支出的增加、政府對臨床試驗的資助以及大規模的研發 (R&D) 活動,這些都有望進一步提振市場。預計未來五年全球非黑色素瘤皮膚癌治療市場將繼續溫和增長。

本報告調查了全球非黑色素瘤皮膚癌市場,包括行業趨勢、市場預測、治療類型/適應症/終端應用/區域市場分析、競爭狀況、主要公司概況等。提供了有關信息。

目錄

第一章前言

第二章範圍和調查方法

第 3 章執行摘要

第 4 章介紹

第 5 章全球非黑色素瘤皮膚癌治療市場

  • 市場概覽
  • 市場表現
  • COVID-19 的影響

第 6 章按治療類型劃分的市場細分

  • 化療
  • 放射治療
  • 光動力療法
  • 其他

第 7 章按適應症劃分的市場

  • 基底細胞癌
  • T 細胞淋巴瘤
  • 鱗狀細胞癌
  • 其他

第 8 章按最終用途劃分的市場細分

  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

第 9 章按地區劃分的市場細分

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東/非洲
    • 按國家/地區劃分的市場細分

第 10 章 SWOT 分析

第11章價值鏈分析

第十二章波特五力分析

第十三章價格分析

第14章競爭形勢

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Accuray Incorporated
    • Almirall S.A.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Elekta AB
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Icad Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Varian Medical Systems Inc.
目錄
Product Code: SR1020F261_Report

The global non-melanoma skin cancer treatment market grew at a CAGR of around 5% during 2015-2020. Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further. Looking forward, IMARC Group expects the global non-melanoma skin cancer treatment market to continue its moderate growth during the next five years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global non-melanoma skin cancer treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, indication and end use.

Breakup by Treatment Type:

  • Chemotherapy
  • Radiation Therapy
  • Photodynamic Therapy
  • Others

Breakup by Indication:

  • Basal Cell Carcinoma
  • T-Cell Lymphoma
  • Squamous Cell Carcinoma
  • Others

Breakup by End Use:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG and Sun Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photodynamic Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Basal Cell Carcinoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 T-Cell Lymphoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Squamous Cell Carcinoma
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Accuray Incorporated
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Almirall S.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Elekta AB
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Icad Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sun Pharmaceutical Industries Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Varian Medical Systems Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Non-Melanoma Skin Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Treatment Type (in %), 2020
  • Figure 4: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Indication (in %), 2020
  • Figure 5: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by End Use (in %), 2020
  • Figure 6: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Region (in %), 2020
  • Figure 7: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 8: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 9: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 10: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2015 & 2020

Figure 11 Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026

  • Figure 12: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 31: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 32: North America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: North America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: United States: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: United States: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: Canada: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: Canada: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: China: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: China: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: Japan: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 43: Japan: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: India: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 45: India: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 46: South Korea: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 47: South Korea: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 48: Australia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 49: Australia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Indonesia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 51: Indonesia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 53: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Europe: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 55: Europe: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: Germany: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 57: Germany: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 58: France: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 59: France: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 60: United Kingdom: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 61: United Kingdom: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 62: Italy: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 63: Italy: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 64: Spain: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 65: Spain: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 66: Russia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 67: Russia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 68: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 69: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 70: Latin America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 71: Latin America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 72: Brazil: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 73: Brazil: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 74: Mexico: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 75: Mexico: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 76: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 77: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 78: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 79: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Breakup by Country (in %), 2020
  • Figure 80: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 81: Global: Non-Melanoma Skin Cancer Treatment Industry: SWOT Analysis
  • Figure 82: Global: Non-Melanoma Skin Cancer Treatment Industry: Value Chain Analysis
  • Figure 83: Global: Non-Melanoma Skin Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Melanoma Skin Cancer Treatment Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2021-2026
  • Table 3: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Indication (in Million US$), 2021-2026
  • Table 4: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by End Use (in Million US$), 2021-2026
  • Table 5: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 6: Global: Non-Melanoma Skin Cancer Treatment Market Structure
  • Table 7: Global: Non-Melanoma Skin Cancer Treatment Market: Key Players